Women experience hair thinning throughout their lifetime due to a variety of factors including hormonal changes, stress, weight loss, and medication. Approximately 50% of women experience hair thinning by the age of fifty [1]. 

Core Biogenesis developed a biotech scalp active featuring biomimetic growth factor FGF-2 delivered using plant-derived oleosomes to address the biological causes of hair thinning and scalp aging. FGF-2 is a signaling growth factor protein that has been studied for its role in tissue regeneration and hair follicle physiology, supporting the biological processes essential to hair growth [2].  

The company’s proprietary whole-plant biofactory technology produces growth factors fused to plant-seed oleosomes which enables 8-10X greater stability, deeper dermal delivery, and accelerated visible results.

The biotech scalp treatment, a formulation containing growth factor FGF-2 (hereafter referred to as Peaureva™ Scalp Serum), demonstrated significantly significant results in an 84-day randomized, blind, placebo-controlled clinical trial against hair and scalp parameters [3]. The Peaureva™ Scalp Serum increased hair density, increased the anagen/telogen ratio, and increased the hair shaft thickness.

The results support that biomimetic growth technologies represent a promising future to healthier and fuller hair, as biomimetic growth factors address multiple biological drivers of hair thinning by stimulating scalp health through topical treatment.

[1] Famenini S, Slaught C, Duan L, Goh C. “Demographics of Women with Female Pattern Hair Loss and the Effectiveness of Spironolactone Therapy.” Journal of the American Academy of Dermatology. October, 2015. 

[2] Nickle A, Ko S, Merrill AE. “Fibroblast Growth Factor 2. Differentiation.” Science Direct. Sept-Oct, 2024.